SOURCE: SRI International

November 18, 2008 11:30 ET

SRI Awarded National Institute on Drug Abuse Contract for Chemical Analysis of Opioid Peptides and Drugs of Abuse

MENLO PARK, CA--(Marketwire - November 18, 2008) - SRI International, an independent, nonprofit research and development organization, announced today that it has been awarded a $1,788,011 contract by the National Institute on Drug Abuse (NIDA). The award is a continuation of two previous NIDA contracts for which SRI has provided chemical analysis of synthetic peptides and related compounds, as well as drugs of abuse. SRI's program will be managed by Kanthi Hettiarachchi, Ph.D., senior chemist in SRI's Biosciences Division.

Under the terms of the contract, SRI researchers will provide NIDA with purity, stability, and authenticity analysis of synthetic peptides and compounds in NIDA's medications development program. To facilitate research on drug abuse, treatment, and prevention, NIDA also operates a drug supply program for researchers. The NIDA Drug Supply Program gives researchers access to authentic and standardized drugs in addition to analytical services.

"SRI International is proud to provide analytical chemistry work that supports NIDA's efforts to reduce drug abuse and addiction," said Helen Parish, senior director of pharmaceutical sciences in SRI's Biosciences Division. "We have experience analyzing all of the drug categories that are of interest to NIDA and are excited to continue this important work."

Since 1972, SRI has worked with NIDA and provided evaluations of potential medicines for the treatment of drug abuse. Changing patterns of drug use have made continued research into more effective treatments a critical part of the research that NIDA supports.

About SRI's Biosciences Division

SRI International's Biosciences Division teams with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important problems in global health. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all of the resources necessary to take R&D programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials -- and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience research. To date, SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI is also working at the nexus of science and technology to create new technology platforms for the next generation of drug discovery and development in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International (www.sri.com) is one of the world's leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2007, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $450 million.

Contact Information

  • Media Contact:
    Dina Basin
    SRI International
    (650) 859-3845
    Email Contact